News

News

September 12, 2022
AnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million
SAN DIEGO , Sept. 12, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that the company has sold its royalty interest on future global net sales of Zejula to a wholly-owned
June 2, 2022
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference
SAN DIEGO , June 02, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Dan Faga , chief
March 21, 2022
AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer
Company to undergo a strategic portfolio review while continuing to execute on the development of its three wholly-owned clinical stage antibody programs SAN DIEGO , March 21, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class
Displaying 1 - 10 of 11